Safety and immunogenicity of a candidate parvovirus B19 vaccine

• Published in: Vaccine Vol. 29; no. 43; pp. 7357 - 7363
• Main Authors: Bernstein, David I., Sahly, Hana M. El, Keitel, Wendy A., Wolff, Mark, Simone, Gina, Segawa, Claire, Wong, Susan, Shelly, Daniel, Young, Neal S., Dempsey, Walla
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Ltd 06.10.2011; Elsevier; Elsevier Limited
• Subjects: Adolescent; Adult; adults; Allergy and Immunology; Antibodies, Neutralizing - biosynthesis; Antibodies, Viral - biosynthesis; Antibodies, Viral - immunology; Applied microbiology; B19; B19 virus; Biological and medical sciences; capsid; Capsid Proteins - immunology; Cell culture; Children & youth; Double-Blind Method; Drug dosages; enzyme-linked immunosorbent assay; erythema; Erythema Infectiosum - prevention & control; Exanthema - etiology; Female; Fundamental and applied biological sciences. Psychology; Hospitals; Humans; immune response; Immunogenicity; Injection; injection site; Licenses; Male; MF59; Microbiology; Middle Aged; Miscellaneous; Mortality; neutralizing antibodies; pain; Parvovirus; Parvovirus B19; Parvovirus B19, Human - immunology; pathogens; Primate erythroparvovirus 1; Proteins; Protoparvovirus; Safety; Vaccine; Vaccines; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects); Vaccines, Synthetic - adverse effects; Vaccines, Synthetic - immunology; Viral Vaccines - adverse effects; Viral Vaccines - immunology; Virology; VLP; Womens health; MF59; B19; Vaccine; Parvovirus; VLP; Virus; Immunogenicity; Parvoviridae; Erythrovirus; Virus B19; Parvovirinae

Parvovirus B19 is an important human pathogen causing erythema infectiosum, transient aplastic crisis in individuals with underlying hemolytic disorders and hydropsfetalis. We therefore evaluated a parvovirus B19 virus like particle (VLP) vaccine. The safety and immunogenicity of a 25μg dose of parv...